Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTKBNASDAQ:EYPTNASDAQ:FEIMNASDAQ:LAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTKBCytek Biosciences$2.59+4.0%$3.43$2.37▼$7.63$328.05M1.42745,849 shs1.04 million shsEYPTEyePoint Pharmaceuticals$7.21+2.4%$5.84$3.91▼$13.99$496.13M1.58822,810 shs757,824 shsFEIMFrequency Electronics$20.26+7.4%$17.36$8.62▼$21.00$196.06M0.3874,673 shs303,901 shsLABStandard BioTools$1.06-2.8%$1.11$0.92▼$2.65$402.61M1.82.13 million shs868,954 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTKBCytek Biosciences+4.02%+5.71%-30.93%-42.32%-55.03%EYPTEyePoint Pharmaceuticals+2.41%+28.75%+8.58%+14.99%-34.22%FEIMFrequency Electronics+7.37%+4.49%+7.71%+28.63%+113.04%LABStandard BioTools-2.75%+11.05%-8.62%-0.47%-59.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTKBCytek Biosciences2.6575 of 5 stars4.12.00.00.02.11.70.6EYPTEyePoint Pharmaceuticals2.4666 of 5 stars3.53.00.00.03.41.70.0FEIMFrequency Electronics2.5654 of 5 stars0.05.00.00.02.84.20.6LABStandard BioTools2.9666 of 5 stars3.33.00.00.02.24.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTKBCytek Biosciences 2.20Hold$5.60116.22% UpsideEYPTEyePoint Pharmaceuticals 3.00Buy$25.38251.94% UpsideFEIMFrequency Electronics 0.00N/AN/AN/ALABStandard BioTools 2.50Moderate Buy$2.50135.85% UpsideCurrent Analyst Ratings BreakdownLatest FEIM, CTKB, LAB, and EYPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/28/2025CTKBCytek BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $7.005/16/2025EYPTEyePoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.005/12/2025CTKBCytek BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$3.50 ➝ $3.005/9/2025CTKBCytek BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$4.005/8/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $27.003/19/2025CTKBCytek BiosciencesStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $6.003/6/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.003/6/2025EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/4/2025CTKBCytek BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.50 ➝ $8.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTKBCytek Biosciences$197.05M1.66$0.01 per share206.16$2.90 per share0.89EYPTEyePoint Pharmaceuticals$56.04M8.85N/AN/A$5.66 per share1.27FEIMFrequency Electronics$65.40M3.00$1.01 per share20.00$4.20 per share4.82LABStandard BioTools$169.69M2.37N/AN/A($1.85) per share-0.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTKBCytek Biosciences-$12.15M-$0.09N/A∞N/A-5.05%-2.58%-2.05%8/5/2025 (Estimated)EYPTEyePoint Pharmaceuticals-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)FEIMFrequency Electronics$5.59M$2.4124.71∞N/A13.02%21.49%9.71%7/21/2025 (Estimated)LABStandard BioTools-$74.66M-$0.35N/AN/AN/A-79.92%-27.05%-15.52%7/30/2025 (Estimated)Latest FEIM, CTKB, LAB, and EYPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CTKBCytek Biosciences-$0.04-$0.09-$0.05-$0.09$43.18 million$41.46 million5/7/2025Q1 2025EYPTEyePoint Pharmaceuticals-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million3/13/2025Q3 2025FEIMFrequency ElectronicsN/A$1.60N/A$1.60N/A$18.93 million3/5/2025Q4 2024EYPTEyePoint Pharmaceuticals-$0.54-$0.64-$0.10-$0.64$11.02 million$11.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTKBCytek BiosciencesN/AN/AN/AN/AN/AEYPTEyePoint PharmaceuticalsN/AN/AN/AN/AN/AFEIMFrequency ElectronicsN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTKBCytek BiosciencesN/A6.215.47EYPTEyePoint PharmaceuticalsN/A5.505.45FEIMFrequency ElectronicsN/A1.790.93LABStandard BioToolsN/A3.763.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTKBCytek Biosciences69.46%EYPTEyePoint Pharmaceuticals99.41%FEIMFrequency Electronics58.60%LABStandard BioTools53.74%Insider OwnershipCompanyInsider OwnershipCTKBCytek Biosciences9.60%EYPTEyePoint Pharmaceuticals4.74%FEIMFrequency Electronics26.10%LABStandard BioTools23.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTKBCytek Biosciences500126.66 million116.45 millionOptionableEYPTEyePoint Pharmaceuticals12068.81 million65.02 millionOptionableFEIMFrequency Electronics2009.68 million7.10 millionNot OptionableLABStandard BioTools620379.82 million174.59 millionOptionableFEIM, CTKB, LAB, and EYPT HeadlinesRecent News About These CompaniesInsider Selling: Standard BioTools Inc. (NASDAQ:LAB) SVP Sells 12,536 Shares of StockMay 24, 2025 | insidertrades.comNorthern Trust Corp Has $5.03 Million Stock Position in Standard BioTools Inc. (NASDAQ:LAB)May 24, 2025 | marketbeat.comParadigm Capital Management Inc. NY Has $435,000 Holdings in Standard BioTools Inc. (NASDAQ:LAB)May 22, 2025 | marketbeat.comStandard BioTools Inc. (NASDAQ:LAB) Shares Sold by Balyasny Asset Management L.P.May 16, 2025 | marketbeat.comStandard BioTools Inc.: Standard BioTools Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finanznachrichten.deStandard BioTools Inc. Earnings Call: Mixed Outlook Amid ChallengesMay 7, 2025 | tipranks.comStandard BioTools outlines $165M-$175M revenue target for FY2025 while driving proteomics partnershipsMay 6, 2025 | msn.comStandard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call TranscriptMay 6, 2025 | seekingalpha.comStandard BioTools (LAB) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comStandard BioTools Reports First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comStandard BioTools Q1 2025 Earnings PreviewMay 5, 2025 | msn.comStandard BioTools (LAB) Expected to Announce Earnings on TuesdayMay 1, 2025 | marketbeat.comStandard BioTools announces new product innovations at AACR 2025April 24, 2025 | markets.businessinsider.comStandard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025April 24, 2025 | globenewswire.comStandard BioTools Inc. to Announce First Quarter 2025 Financial Results on May 6, 2025April 22, 2025 | quiverquant.comStandard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025April 22, 2025 | globenewswire.comCasdin Partners Master Fund, L Buys 4,820,959 Shares of Standard BioTools Inc. (NASDAQ:LAB) StockMarch 5, 2025 | insidertrades.comStandard BioTools Inc. (NASDAQ:LAB) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMarch 1, 2025 | uk.finance.yahoo.comQ4 2024 Standard BioTools Inc Earnings CallFebruary 27, 2025 | uk.finance.yahoo.comStandard BioTools downgraded to Sector Weight from Overweight at KeyBancFebruary 27, 2025 | markets.businessinsider.comKeybanc Downgrades Standard BioTools (LAB)February 27, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsBy Ryan Hasson | May 5, 2025View Rocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsOklo Reaches Critical Mass, Atomic Upside Still AvailableBy Thomas Hughes | May 14, 2025View Oklo Reaches Critical Mass, Atomic Upside Still AvailableRocket Lab: Earnings Miss But Neutron Momentum HoldsBy Ryan Hasson | May 12, 2025View Rocket Lab: Earnings Miss But Neutron Momentum HoldsHims & Hers Stock Soars on Novo Nordisk CollaborationBy Gabriel Osorio-Mazilli | April 30, 2025View Hims & Hers Stock Soars on Novo Nordisk CollaborationRetail Investors Are Betting Big on Rocket Lab—Should You Too?By Ryan Hasson | May 16, 2025View Retail Investors Are Betting Big on Rocket Lab—Should You Too?FEIM, CTKB, LAB, and EYPT Company DescriptionsCytek Biosciences NASDAQ:CTKB$2.59 +0.10 (+4.02%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$2.64 +0.05 (+1.93%) As of 05/29/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.EyePoint Pharmaceuticals NASDAQ:EYPT$7.21 +0.17 (+2.41%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$7.16 -0.05 (-0.69%) As of 05/29/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Frequency Electronics NASDAQ:FEIM$20.26 +1.39 (+7.37%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$20.42 +0.16 (+0.81%) As of 05/29/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Frequency Electronics, Inc., together with its subsidiaries, engages in designing, development, and manufacturing of precision time and frequency control products and components for microwave integrated circuit applications. It operates through two segments, FEI-NY and FEI-Zyfer. The FEI-NY segment offers precision time and frequency control products for communication satellites, terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military; and provides design and technical support for satellite business. FEI-Zyfer segment offers global positioning system technologies to systems and subsystems for secure communications, both government and commercial, and other locator applications; and engages in sale and support of wireline telecommunications products, including US5G. It markets its products directly and through independent sales representative organizations located in the United States, Europe, and Asia. Frequency Electronics, Inc. was founded in 1961 and is headquartered in Mitchel Field, New York.Standard BioTools NASDAQ:LAB$1.06 -0.03 (-2.75%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.06 0.00 (0.00%) As of 05/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
